Company / R&D Expense
Enliven Therapeutics, Inc. R&D Expense History
FY2019-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$80.8M
FY2024
5-year range
$31.0M / $80.8M
FY2020-FY2024
Trend
+25.1%
vs FY2023
Sector context
#155 of 210
Health Care
What the data says
At $81M, Enliven Therapeutics, Inc.'s r&d expense ranks #155 of 210 in the Health Care sector. Improved from $31M to $81M over the past 2 years.
Based on SEC 10-K filings.
$81M in FY2024 with a 5-year CAGR of +33.6%.
Improved from $31M to $81M over the past 2 years.
Health Care sector context is included.
R&D Expense over time
Growth rates
- 3-Year CAGR
- +28.1%
- 5-Year CAGR
- +33.6%
- 10-Year CAGR
- -
Sector benchmark
#155 of 210 in Health CareTop 74% of 210This company $80.8M Sector average $644.0M
▼
-87.5% below sector average
Key checks
Key Insights
- 5-year CAGR of +33.6%, indicating consistent growth.
- In FY2024, r&d expense increased 25.1% year-over-year.
- Ranks #155 out of 210 companies in the Health Care sector.
- Lowest r&d expense in the period was in FY2019.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 7.84 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $80.8M | +25.1% |
| FY2023 | $64.6M | +108.2% |
| FY2022 | $31.0M | -19.3% |
| FY2021 | $38.4M | +19.6% |
| FY2020 | $32.2M | +69.2% |
| FY2019 | $19.0M | - |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026